1. How ‘Optimal’ are Optimal Sampling Times for Tyrosine Kinase Inhibitors in Cancer? Practical Considerations

   • Michael B. Ward
   • Stephanie E. Reuter
   • Jennifer H. Martin

   Leading Article 16 April 2016 Pages: 1171 - 1177

   

2. A New Level A Type IVIVC for the Rational Design of Clinical Trials Toward Regulatory Approval of Generic Polymeric Long-Acting Injectables

   • Mahadevabharath R. Somayaji
   • Debarun Das
   • Andrzej Przekwas

   Current Opinion 27 June 2016 Pages: 1179 - 1190

   

3. Clinical Pharmacokinetics and Pharmacodynamics of Bosutinib

   • Richat Abbas
   • Poe-Hirr Hsyu

   Review Article 25 April 2016 Pages: 1191 - 1204

   

4. Pharmacokinetic and Pharmacodynamic Analyses of 5-Fluorouracil in East-Asian Patients with Nasopharyngeal Carcinoma

   • Yuxiang Ma
   • Yuehao Lin
   • Hongyun Zhao

   Original Research Article 30 April 2016 Pages: 1205 - 1216

   

5. Pharmacodynamic Analysis of Morphine Time-to-Remedication Events in Infants and Young Children After Congenital Heart Surgery

   • Mohammed H. Elkomy
   • David R. Drover
   • Kristi L. Glotzbach

   Original Research Article 20 April 2016 Pages: 1217 - 1226

   

6. Pharmacokinetic Modeling and Dose Selection in a Randomized, Double-Blind, Placebo-Controlled Trial of a Human Recombinant Alkaline Phosphatase in Healthy Volunteers

   • Esther Peters
   • Jules A. A. C. Heuberger
   • Peter Pickkers

   Original Research Article Open access 04 May 2016 Pages: 1227 - 1237

   

7. Pharmacogenetics of UGT1A4, UGT2B7 and UGT2B15 and Their Influence on Tamoxifen Disposition in Asian Breast Cancer Patients

   • Natalia Sutiman
   • Joanne Siok Liu Lim
   • Balram Chowbay

   Original Research Article 20 April 2016 Pages: 1239 - 1250

   

8. Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor

   • Reza Khosravan
   • Robert J. Motzer
   • Brian I. Rini

   Original Research Article Open access 06 May 2016 Pages: 1251 - 1269

   

9. Blinatumomab, a Bispecific T-cell Engager (BiTE^®) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications

   • Min Zhu
   • Benjamin Wu
   • Sameer Doshi

   Original Research Article 21 May 2016 Pages: 1271 - 1288

   

10. Does Weight Impact Anidulafungin Pharmacokinetics?

    • Vincent J. Lempers
    • Anne van Rongen
    • Roger J. Brüggemann

    Short Communication Open access 03 May 2016 Pages: 1289 - 1294